Calidi Biotherapeutics (CLDI) Reports Q3 Net Loss of $3.6M

Calidi reported a Q3 2026 net loss attributable to common stockholders of $3.6M, versus $10.8M in Q3 2025, which included a $5.7M non-cash deemed dividend charge on warrants. Cash was $3.9M at September 30, 2026, versus $5.6M at December 31, 2025.Material DetailsContext by AI AnalystThis is a quart…